Grade 2 isocitrate dehydrogenase 1 or 2 mutant (mIDH1/2) gliomas are diffusely infiltrating brain tumors with an inherent tendency to (malignant) progression. The prognosis of glioma patients with a mutation in one of the two IDH1/IDH2 genes is significantly better than the prognosis of patients with wild-type tumors without IDH1/IDH2 mutations. This is also the reason why the IDH mutational status was introduced into glioma classification, consistently separating IDH-mutant gliomas (astrocytomas and oligodendrogliomas) from IDH-wildtype glioblastoma. Thus, accurate diagnostics of the IDH mutational status turns out to be increasingly important for both diagnostic and predictive purposes.
Due to recent approval in the US and the ongoing regulatory assessment of a targeted therapy against mutated IDH in the EU in the indication of low-grade gliomas, QuIP is organizing the proficiency test IDH1/IDH2 Mutation Analysis in Gliomas (MolPath) 2025:
- Price: 1.000,-€
- Registration period: until 01.08.2025
- Testing period: 20.10.2025 until 07.11.2025
Scientifically independent conducted with the kind support of Servier Deutschland GmbH.
